Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Unusually-High Trading Volume - Time to Buy?

Key Points

• Recursion Pharmaceuticals experienced an unprecedented trading volume of approximately 86.9 million shares, marking a *216% increase* from the previous session.
• Analysts have mixed sentiments on RXRX, with Weiss Ratings issuing a *"sell" rating*, while Needham & Company holds a *"buy" rating* with a price target of $8.00.
• The company's recent earnings report showed a *33.3% year-over-year revenue increase* but a larger-than-expected loss per share of ($0.41), missing consensus estimates.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 86,913,779 shares changed hands during trading, an increase of 216% from the previous session's volume of 27,482,527 shares.The stock last traded at $6.57 and had previously closed at $6.79.

Wall Street Analyst Weigh In

Several analysts have commented on RXRX shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research note on Wednesday, October 8th. Morgan Stanley started coverage on Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price target on the stock. Finally, Needham & Company LLC restated a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, September 11th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $7.25.

Recursion Pharmaceuticals Trading Down 6.4%

The stock has a fifty day moving average of $5.10 and a 200 day moving average of $5.11. The company has a market capitalization of $2.76 billion, a P/E ratio of -3.57 and a beta of 0.91. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.58 and a current ratio of 3.58.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). The company had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.Recursion Pharmaceuticals's revenue for the quarter was up 33.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.40) earnings per share. As a group, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, insider Najat Khan sold 36,599 shares of the firm's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.52, for a total transaction of $202,026.48. Following the sale, the insider directly owned 668,197 shares of the company's stock, valued at $3,688,447.44. This trade represents a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.43% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. TD Waterhouse Canada Inc. increased its holdings in shares of Recursion Pharmaceuticals by 64.1% in the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company's stock worth $29,000 after purchasing an additional 2,200 shares during the last quarter. AlphaQuest LLC bought a new stake in shares of Recursion Pharmaceuticals in the first quarter worth about $36,000. GAMMA Investing LLC increased its holdings in shares of Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after purchasing an additional 2,026 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in shares of Recursion Pharmaceuticals by 97.2% in the second quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company's stock worth $46,000 after purchasing an additional 4,446 shares during the last quarter. Finally, Janney Montgomery Scott LLC bought a new stake in shares of Recursion Pharmaceuticals in the second quarter worth about $51,000. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.